RankingsPricing
  1. US-listed companies
  2. ABEONA THERAPEUTICS INC.

ABEONA THERAPEUTICS INC.ABEO

Market cap
$143.69M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022
Net loss-2,532,000-10,532,0004-26,778,000-14,526,000-21,873,000-27,319,000-56,671,000-76,282,000-84,234,000-84,936,000-40
Depreciation and amortization233,000419,0003,00011,000551,000825,000741,00028533
Stock-based compensation expense-----5587653
Gain on settlement with licensor----------7-
PPP loan payable forgiveness income----------2-
Impairment of goodwill----------32-
Change in fair value of warrant liabilities------------11
Impairment of licensed technology-----------1
Impairment of right-of-use lease assets-----------3
Non-cash impairment of construction-in-progress-----------2
Accretion and interest on short-term investments-----------0
Amortization of right-of-use lease assets----------11
Non-cash interest-----------1
Loss on disposal of property and equipment------------0
Gain on lease termination-----------0
Accounts receivable------------3
Other receivables-----------0
Prepaid expenses and other current assets-31,000212,000-174,000-77,000287,000-160,00031-670,000-424,000-331,000-2
Other assets15,000-17,000-10,000-29,0004,000---3,000127,0007,000-0
Accounts payable, accrued expenses and lease liabilities53,000567,000-1,176,00033,000-1,174,000-------5
Deferred revenue-1,180,000-596,0003-349,000-602,000-602,0002296,000----0
Change in payable to licensor------------5
Net cash used in operating activities-7,609,000-3,955,0001,000----22,935,000-39,111,000-62,820,000-35,019,000-66-43
Capital expenditures40,00013,0002,000-308,000519,000860,00096140
Proceeds from disposal of property and equipment----4------2
Purchases of short-term investments---------1702078
Proceeds from maturities of short-term investments--------66889053
Net cash (used in) provided by investing activities-40,000-13,000-2,000----860,000-85,086,00060-83,714,00066-24
Proceeds from ATM sales of common stock, net of issuance costs6--127---17-813
Proceeds from issuance of common stock and warrants in private offering, net of issuance costs-----------34
Proceeds from exercise of stock options and net settlement of restricted share awards------------0
Proceeds from issuance of Series A and Series B Convertible Redeemable Preferred Stock, net of issuance costs-----------23
Redemption of Series A and Series B Convertible Redeemable Preferred Stock-----------26
Net cash provided by financing activities3229,000---92511422543
Net (decrease)increase in cash, cash equivalents and restricted cash--------118,720,000111-116,797,00025-24
Additions (deletions) to right-of-use lease assets obtained from new operating lease liabilities resulting from modification of original lease arrangement----------4-0
Deletions to operating lease liabilities obtained from new operating lease liabilities resulting from modification of original lease arrangement------------0